A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

AbbVie

Status and phase: Enrolling; Phase 3

Conditions: Functional Constipation (FC); Chronic Idiopathic Constipation (CIC)

Treatments: Drug: Linaclotide; Drug: Placebo for Linaclotide

Study type: Interventional

Funder types: Industry

Identifiers

NCT05652205

2022-501946-31-00 (Other Identifier)

M21-572

Details and patient eligibility

About

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC.

Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients, ages 2 to 5, who meet modified Rome IV criteria for childhood FC. In Part 1 of this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. All participants in Part 2 will receive linaclotide. Approximately 116 participants aged 2 to 5 years with FC will be enrolled in this study at around 45 sites worldwide.

Participants will receive daily doses of oral Linaclotide capsules or matching placebo for 12 weeks in Part 1 of the study. In Part 2, the open label long-term safety extension, participants with FC who completed study intervention in Part 1 of Study M21-572 or the Phase 2 Study LIN-MD-67 will receive linaclotide for 24 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Enrollment: 116 estimated patients

Sex: All

Ages: 2 to 5 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Caregiver/parent/guardian/legally authorized representative (LAR) is willing and able to comply with procedures required in this protocol, prior to the initiation of any screening or study-specific procedures. In addition, the caregiver/parent/guardian/LAR who will be completing the electronic diary (eDiary) must be able to read and understand the assessments in the eDiary device and undergo training.

• Participant meets modified Rome IV criteria for FC: For at least 1 month before Screening (Visit 1), the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) per week. In addition, at least once per week, participant must meet 1 or more of the following:

  • History of retentive posturing or excessive volitional stool retention.
  • History of painful or hard bowel movements (BMs).
  • Presence of a large fecal mass in the rectum.
  • History of large diameter stools.
  • At least 1 episode of fecal incontinence per week after the acquisition of toileting skills, if applicable.

Exclusion criteria

• Participant history of:

  • Celiac disease, or positive serological test for celiac disease or the condition is suspected but has not been ruled out by endoscopic biopsy
  • Cystic fibrosis
  • Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to Screening (Visit 1)
  • Down's syndrome or any other chromosomal disorder
  • Active anal fissure (i.e., participant reports having streaks of blood on the stool or on toilet paper and/or pain/crying with BM within 2 weeks prior to Screening). (Note: anal fissures that have resolved at least 2 weeks prior to screening would not be exclusionary.) However, if in the investigator's opinion, an anal fissure(s) may be the primary cause of participant's modified Rome IV FC criteria, the participant would not be eligible to participate in the study.
  • Anatomic malformations (e.g., imperforate anus, anal stenosis, anterior displaced anus)
  • Intestinal nerve or muscle disorders (e.g., Hirschprung disease, visceral myopathies, visceral neuropathies)
  • Neuropathic conditions (e.g., spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma)
  • Lead toxicity, hypercalcemia
  • Inflammatory bowel disease
  • Childhood functional abdominal pain syndrome
  • Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study
  • Lactose intolerance that is associated with symptoms which could confound the assessments in this study
  • History of cancer. (Note: participants with a history of cancer are allowed provided that the malignancy has been in a complete remission before Randomization (Visit 2). A complete remission is defined as the disappearance of all signs of cancer in response to treatment.)

• Has conditions that could interfere with drug absorption including but not limited to short bowel syndrome.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Quadruple Blind

---

116 participants in 3 patient groups

Part 1 Linaclotide

Experimental group

Description:

Participants will receive linaclotide for 12 weeks.

Treatment:

Drug: Linaclotide

Part 1 Placebo

Experimental group

Description:

Participants will receive placebo for 12 weeks.

Treatment:

Drug: Placebo for Linaclotide

Part 2 Linaclotide

Experimental group

Description:

Participants who completed study intervention in Part 1 of this study or the Phase 2 Study LIN-MD-67 will receive 24 weeks of linaclotide exposure.

Treatment:

Drug: Linaclotide